{
    "nctId": "NCT00943670",
    "briefTitle": "Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression",
    "officialTitle": "A Phase II, Open-Label Study to Evaluate Corrected QT Interval Effects of Trastuzumab-MCC-DM1 (T-DM1) in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer and to Evaluate the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression While Receiving T-DM1 Alone",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 51,
    "primaryOutcomeMeasure": "Change From Baseline in Mean Duration of the QTc Interval",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically documented, locally advanced, or metastatic breast cancer; measurable and/or non-measureable but evaluable disease is permitted\n* HER2-positive disease\n* History of prior trastuzumab therapy\n* Life expectancy \u2265 90 days as assessed by the investigator\n* Negative urine pregnancy test \u2264 72 hours prior to Cycle 1 Day 1 for all women of childbearing potential\n* For patients of childbearing potential, agreement to use one highly effective form of contraception or two effective forms of contraception for the duration of the study treatment(s) and for 4 months after the last dose of T-DM1 or 6 months after the last dose of pertuzumab, if applicable\n\nExclusion Criteria:\n\n* Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy for the treatment of breast cancer within 2 weeks of the first study treatment\n* Prior T-DM1 or pertuzumab therapy\n* History of intolerance (such as Grade 3-4 infusion reaction) and/or adverse events related to trastuzumab\n* Grade \u2265 2 (based on National Cancer Institute Common Terminology Criteria for Adverse Events \\[NCI CTCAE\\] v3) peripheral neuropathy at the time of or within 3 weeks prior to the first study treatment\n* Brain metastases that are untreated or progressive or have required any type of therapy, including radiation, surgery, and/or steroids, to control symptoms from brain metastases within 60 days prior to the first study treatment\n* History of cardiac disease, unstable angina, symptomatic congestive heart failure (CHF) (Class \u2265 II per the New York Heart Associate \\[NYHA\\] guidelines), myocardial infarction, or ventricular arrhythmia \u2264 6 months prior to Cycle 1, Day 1\n* Implantable pacemaker or automatic implantable cardioverter defibrillator\n* Congenital long QT syndrome or family history of long QT syndrome\n* Current uncontrolled hypertension\n* Current treatment with medications that alter cardiac conduction (e.g., digitalis, beta-blockers, or calcium channel blockers) or medications that are generally accepted to have a risk of causing torsades de pointes (TdP)\n* Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus\n* Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment, or anticipation of the need for major surgery during the course of study treatment",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}